Aptevo Therapeutics Inc. announced that Randy J. Maddux has joined the company as Senior Vice President, Operations, effective July 2016.  Mr. Maddux brings more than 30 years of biopharmaceutical operations experience and has served in key roles supporting the licensure and launch of several successful biopharmaceutical products, including, Avonex®, Tysabri®, Benlysta® and Raxibacumab. In his new role at Aptevo, Mr. Maddux will work closely with the research, clinical and regulatory organizations to set strategic direction and provide operational support for the development of novel bispecific antibody candidates derived from Aptevo’s proprietary ADAPTIR™ platform.  He will also provide oversight and direction in support of the supply chain for the Company’s four commercial products – IXINITY®, WINRHO®, HEPAGAM B® and VARIZIG®. Prior to joining Aptevo, Mr. Maddux served as Vice President and Site Director at GlaxoSmithKline, where he led the biopharmaceutical development and manufacturing site within the GSK manufacturing network. The company also announced the promotion of Jane Gross, Ph.D., to the position of Senior Vice President and Chief Scientific Officer.  Jane has been instrumental in advancing the research and non-clinical development efforts for their ADAPTIR™ platform under their predecessor company, Emergent BioSolutions.  Her expertise in immunology and protein therapeutics is an important asset as they strive to develop and advance novel immuno-oncology bispecific antibody candidates based on their ADAPTIR™ platform. Dr. Gross has a Ph.D. in immunology and over twenty-five years of experience in the discovery and development of novel protein therapeutics in autoimmune, infectious disease and oncology indications.